Chromatography Or By Septum Selective As To Material, E.g., Gel Filtration, Molecular Sieve Dialysis, Etc. Patents (Class 530/417)
  • Publication number: 20130315943
    Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
    Type: Application
    Filed: July 15, 2011
    Publication date: November 28, 2013
    Inventors: Shaowei Li, Minxi Wei, Xianglin Kong, Yingbin Wang, Jun Zhang, Ningshao Xia
  • Patent number: 8580935
    Abstract: The present invention relates to a chromatographic method of separating biological material comprising, providing chromatographic media comprising inorganic oxide particles having an average diameter of about 2 microns or less and an average pore diameter of 300 ? or more; applying a solvent comprising said biological material to said media, wherein said biological material is reversibly bonded to said media; and eluting said biological material from said media with a solvent in less than about 2 minutes for biological material having a molecular weight of less than about 100,000 Daltons.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: November 12, 2013
    Assignee: Alltech Associates, Inc.
    Inventors: Reno T. Nguyen, Scott Anderson, Ian Chappell
  • Patent number: 8568594
    Abstract: Embodiments of the present invention are directed to articles of manufacture, devices, methods and apparatus for performing liquid chromatography featuring a chromatographic sorbent having one or more pentafluorophenyl groups, wherein said one or more pentafluorophenyl groups are a bonded phase on a sorbent selected from the group comprising silica, organic polymers or hybrid organic silane material and said pentafluorophenyl groups are in a mono-, bi-, and tridentate forms.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: October 29, 2013
    Assignee: Waters Technologies Corporation
    Inventors: Martin Gilar, Ying-Qing Yu, Jennifer Fournier, John E. O'Gara
  • Publication number: 20130274454
    Abstract: A method for obtaining a liquid from a porous solid phase is described. The method comprises forming a liquid seal at a first end of a porous solid phase to which a liquid is bound, wherein liquid of the liquid seal is immiscible with the liquid bound to the solid phase, and applying a pressure differential across the porous solid phase to cause the immiscible liquid to move through the porous solid phase towards a second end of the porous solid phase, thereby displacing the liquid bound to the porous solid phase towards the second end and releasing this liquid from the second end. Recovery of liquid from the solid phase using such methods is increased compared with corresponding methods in which no liquid seal is formed. In preferred embodiments, the liquid used to form the liquid seal is a mineral oil. The methods have particular application in nucleic acid extractions which utilise capture of nucleic acid to a solid phase. Kits and apparatus for performing the methods are also described.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventor: Cambridge Enterprise Limited
  • Publication number: 20130253142
    Abstract: A novel separating agent for protein purification which not only can adsorb proteins in a sufficient amount for protein purification from a low concentration buffer but also can desorb the adsorbed protein easily just by altering the pH of the buffer and a simple and economical method for its production and a method for protein purification using it. One or two ligands selected from the group consisting of a ligand represented by the following formula (1): (wherein m is an integer of from 2 to 6) and a ligand represented by the following formula (2): (wherein each of R1 and R2 is independently a hydrogen atom or a C1-4 alkyl group, and n is an integer of from 1 to 6) are immobilized on a support via a urethane bond without intervention of a spacer arm.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 26, 2013
    Inventors: Seiji MASUMOTO, Katsuo KOMIYA, Koji NAKAMURA
  • Patent number: 8536315
    Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.
    Type: Grant
    Filed: January 30, 2005
    Date of Patent: September 17, 2013
    Assignee: Shire Pharmaceuticals Ireland Limited
    Inventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Christer Moller, Pia Hyden
  • Patent number: 8530417
    Abstract: The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof.
    Type: Grant
    Filed: December 29, 2007
    Date of Patent: September 10, 2013
    Assignee: Biosteed Gene Expression Tech Co. Ltd.
    Inventors: Shiyuan Wang, Jianhua Zheng, Li Sun, Huili Cai, Meihua Yang, Yan He, Ping Chen, Hongyuan Deng, Liping Zhong, Shuying Huang
  • Patent number: 8519108
    Abstract: The method of the present invention comprising successive column chromatography processes for the purification of an anthrax protective antigen can achieve an improved purity of the anthrax protective antigen product by effectively removing impurities (e.g., cellular residual proteins in the culture solution) without the loss of anthrax protective antigen. Therefore, the method of the present invention can be advantageously used for economically producing the anthrax protective antigen on a large scale.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: August 27, 2013
    Assignees: Korea Center For Disease Control and Prevention, Green Cross Corporation
    Inventors: Hee-Bok Oh, Bong-Su Kim, Gi-Eun Rhie, Jeong-Hoon Chun, Hun Kim, SinKoo Yeo, MahnHoon Park, Chong-Hwan Jonathan Chang, Mi Sun Ahn
  • Publication number: 20130190478
    Abstract: The current invention reports a method for the purification of a non-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second c
    Type: Application
    Filed: September 21, 2012
    Publication date: July 25, 2013
    Inventor: Hoffmann-La Roche Inc.
  • Patent number: 8492524
    Abstract: The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein.
    Type: Grant
    Filed: January 2, 2008
    Date of Patent: July 23, 2013
    Assignee: LFB Biotechnologies
    Inventors: Alain Lejars, Michel Nogre, Monique Ollivier
  • Patent number: 8492530
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: July 23, 2013
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
  • Patent number: 8486481
    Abstract: The invention relates to a process for the removal of glycoalkaloids, in particular from process streams such as those encountered during isolation of proteins from potatoes.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: July 16, 2013
    Assignee: Coöperatie AVEBE U.A.
    Inventors: Marco Luigi Federico Giuseppin, Marc Christiaan Laus
  • Patent number: 8481693
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: July 9, 2013
    Assignee: Takeda Vaccines (Montana), Inc.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Patent number: 8481694
    Abstract: The present invention provides methods of purifying immunoconjugates.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: July 9, 2013
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Mark Snyder
  • Publication number: 20130172535
    Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 4, 2013
    Inventor: Richard L. Gehant
  • Patent number: 8466265
    Abstract: A method of preparing anti-b amyloid immunoglobulin involves treating human plasma anti-b amyloid immunoglobulin under alkaline conditions, such as at pH 10.25 to 11.75 using diethylamine HCl, to dissociate b amyloid protein therefrom. Typically, the anti-b amyloid immunoglobulin is present in human immunoglobulin preparations obtained from plasma or serum. Anti-b amyloid immunoglobulin prepared by the method is substantially free of b amyloid protein and has therapeutic activity in compositions and/or methods for treating a disease or condition associated with b amyloid plaques, such as Alzheimer's disease.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: June 18, 2013
    Assignee: CSL Limited
    Inventor: John Cox
  • Patent number: 8461302
    Abstract: The present invention provides improved methods for the purification of factor XIII. In particular, the methods provide compositions containing 5% or less contaminating proteins. In particular embodiments of the present invention the methods provide purified factor XIII compositions comprising less than 1% activated factor XIII, less than 2% protein aggregates, and/or less than 5% charge isomers of factor XIII. The methods do not require the use a precipitation or crystallization step common to prior methods of isolating factor XIII. Instead, the method uses immobilized metal affinity chromatography to remove various contaminants common to recombinant expression of factor XIII. Further, a combination of various chromatography methods including ion exchange chromatography, hydrophobic affinity chromatography, and immobilized metal affinity chromatography comprise a simple and less expensive method to produce a pharmaceutical grade factor XIII product at high yield.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: June 11, 2013
    Assignee: Zymogenetics, Inc.
    Inventors: Carol Jewell, Hardarshan Cheema, Deborah Hogg, Wenmao Meng, Ray O'Donnell, Ewan Robertson, Andrew Topping
  • Publication number: 20130115693
    Abstract: The present invention refers to a device, comprising a hollow body having at least one open end comprising at least one solid matrix binding, adsorbing, absorbing, chelating or retaining compounds which are not desired in a sample and preferably at least one barrier which is non-permeable for liquids and solids under ambience conditions, however, becomes liquid-permeable by applying an external force to said barrier, the use of such a device for isolating or purifying a biomolecule from a sample, a method for preparation of said device and a method for isolation or purification of any biomolecule using said device.
    Type: Application
    Filed: July 13, 2011
    Publication date: May 9, 2013
    Inventors: Vera Holländer, Markus Müller, Karin Schulte
  • Publication number: 20130096284
    Abstract: In large-scale purification of proteins such as antibodies, an economic high-purity purification method is required. The present invention relates to a method for purifying a protein, including one or more chromatographic processes, in which an amino acid; or a dipeptide, an oligopeptide, or a polyamino acid thereof is included in a buffer solution used in at least one chromatographic processes (equilibration buffer, wash buffer, and elution buffer), thereby purifying a high-purity protein with a very small quantity of the impurity (e.g., polymers or host cell proteins).
    Type: Application
    Filed: June 20, 2011
    Publication date: April 18, 2013
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventor: Takashi Ishihara
  • Patent number: 8399633
    Abstract: During the production of recombinant proteins from gram negative bacteria, lipopolysaccharides (LPS, endotoxin) are released along with the protein of interest. In many instances, LPS will copurify with the target protein due to specific or non-specific protein-ILPS interactions. We have investigated the ability of alkanediols to effect the separation of LPS from protein-LPS complexes while the complexes are immobilized on anion or cation exchange chromatographic media. Alkanediols provide a safer alternative to the use of other organics such as alcohols or acetonitrile due to their lower toxicity and decreased flammability. In addition, they are less costly than many of the detergents that have been used for such purposes. LPS removal efficiency increased with increasing alkane chain length. 1,2-alkanediols were more effective than terminal alkanediols in the separation of LPS from protein LPS complexes.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: March 19, 2013
    Assignee: Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    Inventors: Philip Alfred Ropp, Michael Van Alen Murray
  • Patent number: 8399620
    Abstract: A method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part is described. The invention is advantageous in that it is a single step chromatographic process which does not require adjustment of pH or conductivity during loading step and results in high yield and potency. The process is used for the purification of recombinant compositions of coagulation factor, particularly recombinant Factor VIII.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: March 19, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Susanne Bang, Lars Thim, Johan Karlsson
  • Patent number: 8399631
    Abstract: The present invention relates to compositions, methods for expressing, and related methods for purifying calreticulin that is free of an affinity label or tag (i.e., non-tagged calreticulin). The invention provides useful methods for commercial production of human calreticulin in a bacterial expression system such as Escherichia coli.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: March 19, 2013
    Assignee: Calretex LLC
    Inventors: Marek Michalak, Monika Dabroska
  • Patent number: 8383776
    Abstract: The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: February 26, 2013
    Assignee: Novo Nordisk Health Care AG
    Inventor: Susanne Bang
  • Patent number: 8383783
    Abstract: This invention is directed to methods for removing, preferably simultaneously and in one step, multiple impurities form crude culture samples, and, in particular, the removal of media components, protein, nucleic acids, lipids, and lipopolysaccharides to ultralow levels. Preferably the purification process comprises: (1) binding of the target substance containing one or more contaminants to a chromatography matrix; (2) washing the bound target substance with one or more buffers containing a synergistic combination of a lyotropic agent or organic solvent, a detergent, and a salt component; and (3) desorbing the target substance from the chromatography matrix, so that the eluate contains ultra low levels of contaminants. The reduction of impurities that can be achieved is preferably 91-99.9% as compared to the amount of impurities in the target substance before purification. The invention is also directed to the targets products that have been so purified.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: February 26, 2013
    Assignees: Serum Institute of India, Ltd., Fina BioSolutions, LLC
    Inventors: Andrew Lees, Jayant Sakaram Joshi
  • Publication number: 20130012684
    Abstract: The present invention provides a method for purification of a protein that is conjugated to an albumin binding moiety from a mixture comprising (i) said protein in said conjugated form and (ii) said protein in a form that is not conjugated to said albumin-binding moiety, the method comprising: (a) providing a solid support comprising a substance capable of specifically binding to the albumin binding moiety; (b) contacting said solid support of (a) with said mixture comprising protein and conjugated protein under suitable conditions for binding of the albumin binding moiety to the substance as defined in (a); and (c) eluting components bound to the solid support.
    Type: Application
    Filed: February 3, 2011
    Publication date: January 10, 2013
    Applicant: Novo Nordisk A/S
    Inventor: Jens Buchardt
  • Publication number: 20120271042
    Abstract: The invention provides systems, methods and kits for the separation and/or purification of at least two cellular components selected from genomic DNA, RNA and proteins. The method includes first lysing a biological sample to generate an aqueous solution containing the cellular components; then applying the aqueous solution to a first mineral support under conditions for genomic DNA to bind; and collecting the flowthrough which contains unbound total RNA and proteins. The method further includes applying the flowthrough to a second mineral support under conditions for RNA to bind, and collecting the flowthrough which contains proteins. The genomic DNA and total RNA bound can be eluted while the protein in the flowthrough can be further purified. Further the total RNA isolated could be used to isolate small RNA such as microRNA.
    Type: Application
    Filed: June 28, 2012
    Publication date: October 25, 2012
  • Patent number: 8293876
    Abstract: The present invention relates to a method for obtaining highly purified hydrophobic proteins from cells by extraction using a buffer containing a detergent and removal of said detergent by hydroxyapatite (HA) column chromatography.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: October 23, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Tauer Christa, Mitterer Artur
  • Publication number: 20120264920
    Abstract: The invention is directed to a method for purifying a protein. The method involves providing a sample containing the protein, processing the sample through a capture chromatography resin, inactivating viruses in the sample, and processing through at least one depth filter and ion-exchange membrane.
    Type: Application
    Filed: October 11, 2011
    Publication date: October 18, 2012
    Inventors: Chen Wang, Robert K. Hickman
  • Publication number: 20120253024
    Abstract: The present invention provides a method and automated system for the purification of polypeptides including the direct filtration of solutions containing the polypeptides after purification.
    Type: Application
    Filed: September 10, 2010
    Publication date: October 4, 2012
    Inventors: Mark R. Whickman, Sam Mansoor
  • Patent number: 8273371
    Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: September 25, 2012
    Inventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck
  • Patent number: 8273707
    Abstract: The invention relates to a process for purifying a protein by mixing a protein preparation with a solution having a first salt and a second salt, wherein each salt has a different lyotropic value, and loading the mixture onto a hydrophobic interaction chromatography column. The dynamic capacity of the column for a protein using the two salt combination will be increased compared with the dynamic capacity of the column for either single salt alone.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: September 25, 2012
    Assignee: Amgen Inc.
    Inventors: Anna Senczuk, Ralph Klinke
  • Patent number: 8268974
    Abstract: A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a pore size of at least 70 kDa and eluting with a solution containing detergent. A method for changing an unfolded protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a urea to the solution to unfold the globular protein, applying the solution to a molecular sizing column and eluting with a solution containing detergent. A method for treating cancer comprising the steps of providing a protein, changing the protein into a fibrillar structure, and administering a therapeutically effective amount of the fibrillar structure protein to a patient in need thereof.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: September 18, 2012
    Assignee: Academia Sinica
    Inventors: Shu-Mei Liang, Chun-Yung Huang, Yen-Po Chen, Chi-Ming Liang
  • Publication number: 20120232255
    Abstract: Pretreatment is performed using a pretreatment cartridge for separating substances that is packed with a stationary phase that is coated on its surface with a polymer whose tendency to hydration will change within a temperature range of 0-80° C. and which is capable of changing the affinity between the substance to be separated and the surface of the stationary phase in response to the shrinkage or swelling of the polymer chain due to temperature change. By using this pretreatment cartridge for separating substances, a convenient operation will suffice for a sample solution to be reduced to a solution containing the substance that need be separated from the specimen. If this method of pretreatment is used, useful substances can be separated intact by merely changing the temperature and it becomes possible to perform the subsequent analyzing or fraction collecting operation efficiently.
    Type: Application
    Filed: September 1, 2010
    Publication date: September 13, 2012
    Applicant: TERUO OKANO
    Inventors: Hideko Kanazawa, Teruo Okano
  • Publication number: 20120214966
    Abstract: A process is disclosed for separating biomolecules from an aqueous solution containing the biomolecules and impurities, having different affinities and/or interactions with a solid support. The solution is passed over a fixed bed of chromatographic resin containing at least three zones, with flow of liquid being arranged between adjacent zones and between a last and first zone. Each of several sequences includes at least an adsorption stage, a rinsing stage, or a desorption stage, with each subsequent sequence being carried out by a downstream displacement of fronts in the zones by approximately the same increment before the periodical displacement of the introduction and withdrawal points.
    Type: Application
    Filed: April 17, 2012
    Publication date: August 23, 2012
    Applicant: GROUPE NOVASEP
    Inventors: Marc-André Theoleyre, Stanislas Baudouin, Annick Merrien, Eric Valery, Olivier Ludemann-Hombourger, David Laurent, Margit Holzer
  • Publication number: 20120214974
    Abstract: A spin column device, which contains a rigid porous filter that retains its shape during centrifugation, chromatography methods using the device to isolate a desired substance, e.g., a biological molecule, from other substances in a mixture, and kits containing the device with one or more reagents for use in the method.
    Type: Application
    Filed: May 2, 2012
    Publication date: August 23, 2012
    Applicant: BIOVENTURES, INC.
    Inventor: Elliott P. Dawson
  • Publication number: 20120202978
    Abstract: Herein is reported a method for determining whether a re-useable chromatography column packing, which is used at least for the second time in a purification step of a purification of a polypeptide, has reduced separation efficacy in said purification step of said purification of said polypeptide, comprising the following steps: a) identifying and determining the experimental data of an inert change of at least one physicochemical parameter of a mobile phase passing through said re-useable chromatography column packing, b) determining the parameters of a function of formula I by fitting the experimental data of the inert change of the physicochemical parameter of the at least second use, c) determining the difference between the experimental data of the inert change of the physicochemical parameter of the at least second use and the function of formula I with the parameters determined in step b), d) calculating the difference between the maximum value and the minimum value of the difference determined in step
    Type: Application
    Filed: June 22, 2010
    Publication date: August 9, 2012
    Applicant: HOFFMANN-LA ROCHE, INC,
    Inventors: Anton Belousov, Thomas Dams, Benjamin Gerwat
  • Patent number: 8227599
    Abstract: A process for the separation of biological materials, such as dye-ligand affinity chromatography, wherein an adsorbent is used, which comprises a reaction product of certain reactive anthroquinone compounds and a substrate having a group capable of reaction with a reactive group in said reactive anthroquinone compounds to form a covalent bond.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: July 24, 2012
    Assignee: BASF SE
    Inventors: Vadiraj Subbanna Ekkundi, Narayan S. Punekar, Kamalesh Pai Fondekar, Georg Roentgen, Shilpa S. Korde, Ajit B. Shinde, Masana Moorthy
  • Publication number: 20120177610
    Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.
    Type: Application
    Filed: May 24, 2011
    Publication date: July 12, 2012
    Inventor: Kieu Hoang
  • Publication number: 20120165268
    Abstract: Biologically active tetrameric p53 proteins and p53 fusion proteins are provided. These proteins may be generated and refolded into tetrameric form using denatured proteins produced from E. coli. Therapeutic uses of p53 proteins and p53 fusion proteins are also provided.
    Type: Application
    Filed: May 28, 2009
    Publication date: June 28, 2012
    Applicant: Proteom Tech, Inc.
    Inventors: Xinli Lin, Michelle Lafevre-Bernt
  • Patent number: 8192999
    Abstract: There is provided a method for the identification of macromolecule targets of analytes such as drugs in biological samples comprising complex mixtures of macromolecules. A biological sample is contacted with one or more analyte and the mixture is resolved such that the analyte and its target are co-eluted and analyzed to identify analyte-target complexes.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: June 5, 2012
    Inventor: Andrew Emili
  • Publication number: 20120122076
    Abstract: The present invention relates to compositions and methods for the chromatographic purification of antibodies, such as monoclonal antibodies, employing improved simulated moving bed separation strategies and, in certain embodiments, Raman spectroscopy.
    Type: Application
    Filed: September 16, 2011
    Publication date: May 17, 2012
    Applicant: Abbott Laboratories
    Inventors: Siu-Man Lau, Diane Dong, Stephen Lu
  • Patent number: 8178108
    Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: May 15, 2012
    Assignee: Ambrx, Inc.
    Inventors: Ying Buechler, Ricky Lieu, Michael Ong, Stuart Bussell, Nick Knudsen, Ho Sung Cho
  • Patent number: 8133521
    Abstract: The present invention relates to methods for the separation of various components from eggs. More particularly, the present invention relates to methods for the separation of proteins and lipids from eggs, including technical eggs (inedible) or edible eggs, yolks or whites, which comprises cross-linking the lipids of eggs with a cross-linking reagent. In an embodiment, the method includes separating the proteins from the cross-linked lipids. In an embodiment, the method includes the separation of various components associated with the cross-linked lipids. The methods disclosed herein allow for the isolation of multiple different components from the egg in an efficient, cost-effective manner without compromising the recovery process of the components or their subsequent utility in various applications or compositions. The compositions and isolated components obtained by the methods of the invention can be used in pharmaceutical, medical, nutritional, cosmetic or health applications.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: March 13, 2012
    Assignee: Biova, L.L.C.
    Inventors: Ronald E. Strohbehn, Jesse I. Figgins
  • Patent number: 8129507
    Abstract: An atopic dermatitis inducer binding to a human own IgE antibody and activating mast cells and basophiles, which includes a purified human secretion fraction, or an antigenic molecule or an antigenic determinant in the purified fraction, and obtained through the following steps of: filtering a human secretion, removing insoluble matters and collecting the filtrate; mixing the filtrate with a ConA-affinity carrier and collecting the supernatant; and separating a component having a histamine-releasing activity from the supernatant by column chromatography. This inducer is effective in diagnosing and treating human atopic dermatitis.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: March 6, 2012
    Assignee: Shionogi & Co., Ltd.
    Inventors: Michihiro Hide, Toshihiko Tanaka, Akio Tanaka, Kaori Ishii, Hidenori Suzuki
  • Patent number: 8124377
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: February 28, 2012
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang
  • Publication number: 20120039920
    Abstract: A composition is disclosed comprising a hydrophobic monomer having the structure: CH2?CR4C(O)NHC(R1R1)(C(R1R1))nC(O)XR3 wherein n is an integer of 0 or 1; R1 is independently selected from at least one of: a hydrogen atom, alkyls aryls, and alkylaryls, wherein the alkyls, aryls, and alkylaryls have a total of 10 carbon atoms or less; R3 is a hydrophobic group selected from at least one of: alkyls, aryls, alkylaryls and ethers, wherein the alkyls, aryls, alkylaryls and ethers have a total number of carbon atoms ranging from 4 to 30; R4 H or CH3; X is O or NH. In some embodiments the hydrophobic monomer is derived from an amine or an alcohol (HXR3) that has a hydrophilicity index of 25 or less. A polymerizable composition comprising the hydrophobic monomer is disclosed, which optionally may comprise a cross-linking monomer and/or a non-cross-linking monomer.
    Type: Application
    Filed: March 19, 2010
    Publication date: February 16, 2012
    Inventors: Jerald K. Rasmussen, Cary A. Kipke, James I. Hembre, Peter D. Wickert
  • Publication number: 20120029176
    Abstract: Adsorptive media for chromatography, particularly ion-exchange chromatography, derived from a shaped fiber. In certain embodiments, the functionalized shaped fiber presents a fibrillated or ridged structure which greatly increases the surface area of the fibers when compared to ordinary fibers. Also disclosed herein is a method to add surface pendant functional groups that provides cation-exchange or anion-exchange functionality to the high surface area fibers. This pendant functionality is useful for the ion-exchange chromatographic purification of biomolecules, such as monoclonal antibodies (mAbs).
    Type: Application
    Filed: July 27, 2011
    Publication date: February 2, 2012
    Inventors: David Yavorsky, John Amara, Joaquin Umana, William Cataldo, Mikhail Kozlov, Matthew Stone
  • Publication number: 20120018380
    Abstract: A chromatography column that captures components in a process liquid in a free flow state and allows elution in steps is described.
    Type: Application
    Filed: September 27, 2011
    Publication date: January 26, 2012
    Applicant: Therapeutic Proteins Inc.
    Inventor: Sarfaraz K. Niazi
  • Publication number: 20120022228
    Abstract: A process for purifying at least one product from a substrate containing at least one product, includes subjecting the substrate to centrifugal partition chromatography in an ion exchange displacement mode to purify the at least one product from the substrate, the at least one product being an amphoteric product.
    Type: Application
    Filed: June 16, 2011
    Publication date: January 26, 2012
    Inventors: Matthieu GIRAUD, John MCGARRITY, Jean-Hugues RENAULT, Leslie BOUDESOCQUE
  • Patent number: RE43655
    Abstract: An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to affect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: September 11, 2012
    Assignee: Bayer HealthCare LLC
    Inventors: Wytold R. Lebing, Douglas C. Lee, Klaus-Peter Radtke, Scott A. Cook, Hanns-Ingolf Paul, Patricia Alred